Description/Abstract
This study examines the effect of health on SSDI outcomes. The effect is identified by a new antiretroviral therapy to treat the human immunodeficiency virus. Administrative data on SSDI applications come from the Disability Research File. According to the analysis, the new therapy had an immediate and persistent effect on program entry. By 1997, the therapy decreased applications by 35.2 percent and new awards by 36.7 percent. Among existing beneficiaries, the therapy decreased program exits through death, but did not substantially increase program exits for work. By 1999, the therapy increased HIV-related expenditures by $43.6 million.
Document Type
Working Paper
Date
Fall 9-2015
Keywords
Health, HIV, Social Security, Disability Insurance
Language
English
Series
Working Papers Series
Disciplines
Economics | Health Policy | Public Affairs, Public Policy and Public Administration | Social Welfare
ISSN
1525-3066
Recommended Citation
Singleton, Perry, "Health, Medical Innovation and Disability Insurance: A Case Study of HIV Antiretroviral Therapy" (2015). Center for Policy Research. 210.
https://surface.syr.edu/cpr/210
Accessible PDF version
Source
Local input
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Included in
Economics Commons, Health Policy Commons, Social Welfare Commons
Additional Information
Working paper no. 182
The author thanks Kimberly Burham, Jeffrey Kubik, Timothy Moore, and David Pattison for helpful comments and suggestions. The author also thanks Patrice Cole for valuable data assistance. This research is supported by a personnel agreement between Syracuse University and the Social Security Administration. The views herein are the authors and do not reflect those of the Social Security Administration.